Ligand Pharmaceuticals Incorporated - Common Stock (LGND)

A high-conviction fund just trimmed one of its biggest winners—here’s what long-term investors should make of the move.

A specialist small-cap fund just doubled down on a digital-intelligence company that's underperforming the broader market.

One fund just took a step back from a struggling energy name—right as the company suspended its dividend to fund future growth.

Pelthos Therapeutics acquires U.S. rights to Xepi Cream and raises $18 million to fund its relaunch and expand dermatology product offerings.

Ligand (LGND) Q3 2025 Earnings Call Transcript

San Diego, CA – November 6, 2025 – Ligand Pharmaceuticals (NASDAQ: LGND) has recently captured the financial spotlight, with its stock hitting a remarkable 52-week high of $197.78 on November 6, 2025. This significant milestone comes on the heels of a robust third-quarter 2025 earnings report that dramatically exceeded analyst expectations,

Ligand (LGND) smashed Q3 2025 earnings estimates, driven by 47% royalty growth. The company also raised its full-year 2025 revenue and EPS guidance.

Johnson & Johnson (NYSE: JNJ), the global healthcare titan, has once again underscored its formidable market position and unwavering commitment to shareholder value, reporting a robust second quarter for 2025. The company's performance was marked by significant growth across its Innovative Medicine and MedTech segments, showcasing the strategic success of its

Ligand Pharmaceuticals (LGND) beat Q2 2025 earnings estimates with strong royalty growth, raising full-year guidance. Stock dipped slightly pre-market but gained 16.3% over the past month.

The launch triggered a $5 million milestone payment to Ligand, which also holds a 56% stake in Pelthos and is eligible for royalties and additional commercial milestones.

Pelthos launches Zelsuvmi, the first FDA-approved at-home prescription gel for molluscum, shown to clear lesions in as little as two weeks.

Under the agreement, Ligand’s wholly owned subsidiaries, Pelthos Therapeutics Inc. and LNHC, Inc. will combine with CHRO Merger Sub Inc., a wholly-owned subsidiary of Channel.

Ligand and Channel Therapeutics to merge in $50 million deal to launch Zelsuvmi for molluscum and advance NaV 1.7 chronic pain programs.

Ligand earns Buy rating from Stifel for its royalty-based funding model and biotech partnerships amid strong revenue and earnings growth.